Newly published data from a cohort of patients receiving doxorubicin-containing regimens for newly diagnosed T-cell acute lymphoblastic leukaemia or lymphoblastic non-Hodgkin lymphoma reveal that addition of dexrazoxane ameliorates the cardiotoxic effects of doxorubicin. No significant differences in overall survival, or in the incidence of treatment-related adverse events were observed; however, significant improvements were observed in a range of cardiac parameters in the dexrazoxane plus chemotherapy group; these effects were sustained up to 6.4 years after diagnosis.